Cyclacel Pharmaceuticals, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines targeting cell cycle control, epigenetics, and mitosis biology. The company’s main products include fadraciclib, a highly selective dual inhibitor of cyclin-dependent kinases CDK2 and CDK9, and plogosertib, a polo-like kinase 1 (PLK1) inhibitor, both of which are in clinical development for treating solid tumors, hematological malignancies, and rare cancers such as fibrolamellar hepatocellular carcinoma. Cyclacel also advances drug candidates in preclinical stages, emphasizing oral anticancer therapies. Its product pipeline aims to address oncology and hematology indications through novel small-molecule inhibitors. The company operates primarily in the United States and has research collaborations with leading cancer research institutions, including MD Anderson Cancer Center and Dana-Farber Cancer Institute. Founded in 1996 and headquartered in Berkeley Heights, New Jersey, Cyclacel combines internal drug development with strategic alliances to expand its pipeline and clinical programs. Recent major developments include executing a share exchange agreement to make FITTERS Diversified Berhad, an investment holding company in Malaysia engaged in fire safety and related businesses, a wholly owned subsidiary to accelerate growth and stockholder value. In 2025, Cyclacel announced promising preclinical data showing the efficacy of plogosertib against difficult-to-treat cancers such as biliary tract cancer and fibrolamellar hepatocellular carcinoma. The company also completed private placement offerings of convertible preferred stock to fund operations and clinical advancements and changed its auditor to SFAI Malaysia PLT. Cyclacel’s strategy emphasizes building a diversified biopharmaceutical business based on a pipeline of novel drug candidates while maintaining rights to core oncology assets through early clinical development phases. The company continues to focus on expanding treatment options globally for cancer patients through innovation in cell cycle biology therapies. Its operational scope includes advancing clinical trial programs, publishing supporting preclinical research, and pursuing strategic partnerships. Cyclacel Pharmaceuticals trades publicly on NASDAQ under the ticker CYCC. This consolidated profile reflects Cyclacel Pharmaceuticals’ status as a development-stage firm at the forefront of targeted cancer therapy, combining cutting-edge science, institutional collaborations, and recent corporate restructuring to enhance its growth trajectory and market presence.
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB
Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?
CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER
Cyclacel Pharmaceuticals Announces Stock Split
Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock
CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT
CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock
Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update